Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2019

Open Access 01-06-2019 | Lung Cancer | short review

Whom to screen? A view on lung cancer screening from the pneumologist’s perspective

Authors: Malte Asshoff, Günter Weiss, Ivan Tancevski

Published in: memo - Magazine of European Medical Oncology | Issue 2/2019

Login to get access

Summary

The benefits of screening programs are highly dependent on risk group definition. This is especially true for lung cancer screening. Results from the National Lung Cancer Screening Trial (NLST) and the NELSON trial (Dutch/Belgian randomised lung cancer screening trial) demonstrated that lung cancer screening using low-dose CT scans results in reduction of cancer-related mortality. This article gives a short overview on participant selection in the NLST and NELSON trials, and on current evidence for implementation of multivariable risk prediction models.
Literature
1.
Stewart BW, Wild CP, editors. WHO world cancer report world cancer report. 2014.
2.
3.
Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. Thorax. 2013;68:551–64.CrossRef
4.
National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.CrossRef
5.
DeKoning H, Van Der Aalst C, TenHaaf K, et al. Effects of volume CT lung cancer screening: mortality results of the NELSON randomized-controlled population based trial. World Conference on Lung Cancer; 25.9.2018. 2018. Abstract PL02.05.
6.
Virginia A. Moyer, MD, MPH; on behalf of the U.S. Preventive services task force. Screening for lung cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2014;160(5):330–8.
7.
Kovalchik S, Tammemagi M, Berg C, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013;369:245–54.CrossRef
8.
Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007;99:715–26.CrossRef
9.
Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95(6):470–8.CrossRef
10.
Knoke JD, Burns DM, Thun MJ. The change in excess risk of lung cancer attributable to smoking following smoking cessation: an examination of different analytic approaches using CPS-I data. Cancer Causes Control. 2007;19(2):207–19.CrossRef
11.
Meza R, Hazelton WD, Colditz GA, Moolgavkar SH. Analysis of lung cancer incidence in the nurses’ health and the health professionals’ follow-up studies using a multistage carcinogenesis model. Cancer Causes Control. 2008;19(3):317–28.CrossRef
12.
Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008;98:270–6.CrossRef
13.
Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368:728–36.CrossRef
14.
TenHaaf K, Jeon J, Tammemägi MC, et al. Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. Plos Med. 2017;4(14):e1002277.CrossRef
15.
Li K, Hüsing A, Sookthai D, et al. Selecting high-risk individuals for lung cancer screening: a prospective evaluation of existing risk models and eligibility criteria in the German EPIC cohort. Cancer Prev Res (Phila). 2015;8:777–85.CrossRef
16.
Weber M, Yap S, Goldsbury D, Manners D, Tammemagi M, et al. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCOm2012 risk prediction tool. Int J Cancer. 2017;141(2):242–53.CrossRef
17.
Raji OY, Duffy SW, Agbaje OF, et al. Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med. 2012;157:242–50.CrossRef
18.
Field JK, Duffy SW, Baldwin DR, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016;20:1–146.CrossRef
19.
AamliGagnat A, Gjerdevik M, Gallefoss F, Coxson HO, Gulsvik A, Bakke P. Incidence of non-pulmonary cancer and lung cancer by amount of emphysema and airway wall thickness: a community-based cohort. ERJ Open Res. 2017;49:1601162.
Metadata
Title
Whom to screen? A view on lung cancer screening from the pneumologist’s perspective
Authors
Malte Asshoff
Günter Weiss
Ivan Tancevski
Publication date
01-06-2019
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2019
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-0501-x

Other articles of this Issue 2/2019

memo - Magazine of European Medical Oncology 2/2019 Go to the issue

case report

Solitary scalp metastatic lesion as a sign of breast cancer recurrence—a case report

short review

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: new avenues and strategies to overcome resistance

short review

Resistance to anti-hormonal therapy in prostate cancer

editorial

Overcoming resistance and bypassing checkpoints—possible new therapeutic frontiers in oncology

obituary

Obituary for Professor Michael Steurer

case report

Seasonal fever for 11 years! A presentation of hemophagocytic lymphohistiocytosis secondary to marginal zone lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits